Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).

@article{Tahara2018PhaseIT,
  title={Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).},
  author={Makoto Tahara and Naomi Kiyota and Tomoya Yokota and Yasuhisa Hasegawa and Kei Muro and Shunji Takahashi and Takuma Onoe and Akihiro Homma and Jun Taguchi and Munetaka Suzuki and Koichi Minato and Katsunari Yane and Shinya Ueda and Hiroki Hara and Ken Saijo and Takeharu Yamanaka},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2018},
  volume={29 4},
  pages={1004-1009}
}
Background The standard of care for first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) is combination treatment with platinum, 5-FU and cetuximab (PFE). However, this regimen requires hospitalization to ensure proper hydration and continuous infusion of 5-FU, and causes severe nausea and anorexia. We evaluated the efficacy and safety of paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with R/M SCCHN… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS